Loading
A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer is a phase 2 interventional study registered as NCT05640791 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 40 participants, started 2023-01-12 and due to reach its primary completion in 2023-12-31. Interventions recorded: Cisplatin, Gemcitabine, Nab-paclitaxel, Durvalumab. Conditions listed: Resectable Biliary Tract Cancer. Sites: China. No results are recorded here; the registry entry is the source.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.